

# Doctor's Note — Clinical Trial Summary

Generated by FindMyCure.ai on April 2, 2026 | For discussion with your oncologist

## TRIAL

### A Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and/or Metastatic Solid Tumors Known to Express c-Kit

NCT ID: NCT06805825 Phase: PHASE1 Sponsor: Novely Nobility, Inc. Status: Recruiting

## SUMMARY

This open-label clinical trial will evaluate the safety and tolerability of NN3201 in subjects with advanced and/or metastatic solid tumors known to express c-Kit.

## KEY ELIGIBILITY CRITERIA

- Subjects must meet the following criteria to be eligible for enrollment into the study:
  - 1. Histologically or cytologically confirmed locally advanced, metastatic, and/or unresectable GIST, SCLC, ACC, uveal melanoma, NET ChRCC or ccRCC.
  - 2. Subjects must have received the following treatment:
    - Part A (Dose Escalation):
      - i. Treatment with imatinib for GIST (at least one line of therapy with imatinib)
      - ii. Progressive/refractory, ineligible, or intolerant to available standard therapy (or subject declines standard therapy) for c-Kit-associated solid tumors (ACC, uveal melanoma, NET ChRCC or ccRCC)
    - Part B (Dose Expansion):
      - i. Treatment with imatinib for GIST (at least one line of therapy with imatinib) or
      - ii. Progressive/refractory, ineligible, or intolerant to available standard therapy (or subject declines standard therapy) for Extensive stage SCLC or
      - iii. Progressive/refractory, ineligible, or intolerant to available standard therapy (or subject declines standard therapy) for c-Kit-associated solid tumors (ACC, uveal melanoma, NET or ChRCC or ccRCC).

## ENROLLMENT CONTACT

### Rashmi Chugh, MD

University of Michigan Hospitals  
Ann Arbor, Michigan, United States  
Phone: 734-709-2415  
Email: rashmim@med.umich.edu

Total sites: 5 | 4 currently recruiting